Pfizer building $465M sterile injectables plant at its Michigan site

Pfizer sign
Pfizer will break ground next year on a 400,000-square-foot, $465 million sterile manufacturing plant. (Tracy Staton)

Pfizer has committed to building a massive, $465 million sterile manufacturing plant at its site in Michigan that is expected to add 450 new jobs by the time it is fully operational.

Pfizer said on Monday that it expects to break ground next spring on the 400,000-square-foot facility in Portage, Michigan, with construction slated to be complete in 2021 and production to begin in 2024.

The plant will include multiple self-contained modular manufacturing lines, allowing the manufacturing line in each module to be entirely separate from all other manufacturing lines, Pfizer said.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“This investment is part of our overall plan announced in January to invest approximately $5 billion in U.S.-based capital projects as a result of the enactment of the Tax Cuts and Jobs Act,” Pfizer CEO Ian Read said in a release.

RELATED: Pfizer seeks big tax break for its massive Michigan manufacturing facility

Locally, the company has also received an $11.5 million local tax abatement from the Michigan Strategic Fund, Bloomberg reports

Pfizer said its Portage site is one of its primary facilities for sterile injectables, liquids and semisolid medicines, as well as active pharmaceutical ingredients. It currently manufactures more than 150 products. Its biggest product is Solu-Medrol, an injectable anti-inflammatory medicine. The 450 jobs it says it will add are in addition to the 2,200 employees already working at the site.

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.